The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Frequency of severe neutropenia occurring as an adverse events of gemcitabine plus cisplatin chemotherapy in patients with recurrent biliary tract cancer compared to those with unresectable biliary tract cancer.
 
Noriko Fujishiro
No Relationships to Disclose
 
Shuichi Mitsunaga
No Relationships to Disclose
 
Akira Shinohara
No Relationships to Disclose
 
Misaki K Takeno
No Relationships to Disclose
 
Hideki Funazaki
No Relationships to Disclose
 
Gen Kimura
No Relationships to Disclose
 
Kazuo Watanabe
No Relationships to Disclose
 
Kumiko Umemoto
No Relationships to Disclose
 
Mitsuhito Sasaki
No Relationships to Disclose
 
Hideaki Takahashi
No Relationships to Disclose
 
Hiroshi Imaoka
No Relationships to Disclose
 
Yusuke Hashimoto
No Relationships to Disclose
 
Izumi Ohno
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kowa; Lilly Japan; Nippon Kayaku; Novartis Pharmaceuticals UK Ltd.; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - AstraZeneca; Baxter; Bayer Yakuhin; Boehringer Ingelheim; Eisai; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical